dorzolamide / Generic mfg. - LARVOL DELTA

Adduct formation by coeluting endogenous biomolecules using ESI-MS : A comprehensive study on ESI efficiency. (PubMed, Anal Bioanal Chem) - "For compounds with a high(er) structural similarity to hydrochlorothiazide (namely: bendroflumethiazide, buthiazide, cyclopenthiazide, and dorzolamide), adduct formation was observed. This study provided new insights into the ESI process."

Journal • ER

Peripapillary retinoschisis associated with open angle glaucoma responding to dorzolamide. (PubMed, Retin Cases Brief Rep) - "We present a case of peripapillary retinoschisis in a phakic patient that developed during treatment with a topical prostaglandin analogue. The schisis resolved after switching the prostaglandin analogue to a topical carbonic anhydrase inhibitor. We suggest that the prostaglandin may have had a role in initiating peripapillary retinoschisis associated with glaucomatous optic neuropathy and that carbonic anhydrase inhibitors are a potential treatment for this condition."

Journal • Glaucoma • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders

STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - P3 | N=28 | Terminated | Sponsor: University of Miami | N=500 ➔ 28 | Completed ➔ Terminated; No patients had abnormal PERG and could not be included in the first two arms from the baseline timepoint.

Enrollment change • Trial termination • Glaucoma • Ophthalmology

Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma. (PubMed, Vet Ophthalmol) - "Topical CAIs appear to result in temporary IOP control in a subset of horses, though some horses may be refractory. Episcleral brinzolamide implants may extend IOP control in horses with glaucoma, but prognosis for vision remains guarded and further optimization is needed."

Journal • Retrospective data • Glaucoma • Ophthalmology

Inhibiting TIRAP-mediated inflammatory signaling: A promising therapeutic strategy against sepsis. (PubMed, Biochem Pharmacol) - "In vitro analyses also confirmed the ability of LeDoz to attenuate TIRAP-mediated inflammatory signaling. Thus, the combination of levofloxacin and dorzolamide exhibits both an antibacterial effect and a strong potential for synergistically reducing chronic inflammation in the host by inhibiting the activation of TIRAP."

Journal • Infectious Disease • Inflammation • Septic Shock

Green Synthesis of Sulfonamide Derivatives as Human Carbonic Anhydrase Isoforms I, II, IX, XII Inhibitors and Antioxidants: Comprehensive Insights From Biological Evaluation and In-Depth In Silico Analysis. (PubMed, J Biochem Mol Toxicol) - "These sulfonamides exhibited significant inhibition compared to standard carbonic anhydrase inhibitors such as acetazolamide, ethoxzolamide, zonisamide, methazolamide, dorzolamide, and SLC-0111. ADMET predictions indicated favorable physicochemical properties and compliance with Lipinski's rule. These results highlight the potential of these aromatic sulfonamide derivatives as potent inhibitors of human carbonic anhydrase isoforms, with promising antioxidant activity, suggesting their potential therapeutic applications in conditions such as retinal and cerebral edema, glaucoma, epilepsy, high-altitude sickness, and cancer."

Journal • CNS Disorders • Epilepsy • Glaucoma • Oncology • Ophthalmology

Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights. (PubMed, Comput Biol Chem) - "This review meticulously examines the development, design, and pharmacological assessment of both well known antiviral and antihypertensive medications all time employing new chemical techniques and structure-based drug design to design and synthesize vital therapeutic entities such as aliskiren (renin inhibitor), captopril (a2-ACE-Inhibitor), dorzolamide (inhibitor of carbonic anhydrase) the review demonstrates initial steps regarding the significance of stereoselective synthesis, metal chelating pharmacophores, and rational molecular properties. More importantly, protease inhibitors (i.e., saquinavir, ritonavir, indinavir, amprenavir, etc.) and more contemporary agents (i.e., oseltamivir, nirmatrelvir/ritonavir (Paxlovid), etc.) were identified in the review and form a basis of advancement in antiviral therapy...In conclusion, this review highlights the transformative power of interdisciplinary approaches, including structure-based design, computational modeling, and..."

Journal • Review • Cardiovascular • Infectious Disease

Anti-Glioblastoma Effects of Dorzolamide Alone and in Combination with Temozolomide on U87 Cells and CD133+Glioblastoma Stem Cells. (PubMed, Curr Mol Med) - "Dorzolamide inhibits GSC proliferation, promotes apoptosis in U87 cells, affects the cell cycle, and enhances TMZ activity, suggesting potential in GBM treatment."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • BCL3 • CA2 • CD133

Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost. (PubMed, Clin Ophthalmol) - P4 | "Adding a fourth hypotensive agent may offer an effective option for patients needing more IOP reduction beyond TD-L, highlighting their role in managing glaucoma in regions with high socioeconomic burdens and limited treatment access. ClinicalTrials.gov identifier NCT04702789, registered on 21 October 2019."

Clinical • Journal • Glaucoma • Ophthalmology

In vitro, ex vivo, and in vivo evaluation of polysaccharide based thermo-sensitive in situ gel for the treatment of glaucoma. (PubMed, J Biomater Appl) - "Then, a TSP-based thermo-sensitive in situ gel-forming solution loaded with dorzolamide hydrochloride (2% w/v) was developed and evaluated through in vitro, ex vivo, and in vivo tests...The safety and efficacy of the formulation were confirmed through an in vivo study on rabbit eyes with induced glaucoma. The findings indicate that the in situ gel significantly reduced intraocular pressure (IOP), with effects comparable to those of marketed eye drops."

Journal • Preclinical • Glaucoma • Ophthalmology

Choroidal effusion after initiation of topical dorzolamide treatment. (PubMed, Drug Ther Bull) - No abstract available

Journal • Glaucoma • Ophthalmology

Comparison of Dorzolamide and Netarsudil on Intraocular Pressure and Ocular Perfusion in Early Glaucoma: A Randomized Controlled Trial. (PubMed, J Glaucoma) - "Netarsudil causes an increase in all the OCTA parameters - mVD, ONH perfusion, and ONH FI whereas Dorzolamide causes an increase only in ONH perfusion in preperimetric/early glaucoma patients. Netarsudil monotherapy also showed a higher decrease in IOP as compared to dorzolamide therapy."

Journal • Glaucoma • Ophthalmology

Effects of Topical Coenzyme Q10 in Conjunction With Vitamin E on the Pattern Visual Evoked Potential, Visual Field, Retinal Ganglion Cell Layer and Retinal Nerve Fibre Layer Thickness in Patients with Primary Open-angle Glaucoma. (PubMed, Photodiagnosis Photodyn Ther) - "Currently, neuroprotective drug studies in glaucoma are increasing daily.These results suggest that Coqun® administration in POAG had a beneficial effect on the inner retinal layer with consequent enhancement of the visual cortical responses (VEP improvement),visual field (decreased MD) and protect RNFL thickness."

Journal • Glaucoma • Ophthalmology

Selective laser trabeculoplasty as an effective method of reducing intraocular pressure in myopic patient after LASIK with primary open-angle glaucoma in a 3-month follow-up period – a case report (SOE 2025) - "The real IOP values reached 21.57 mmHg in the right eye (the measured IOP was 19 mmHg) and 20.22 mmHg in the left eye (the measured IOP was 18 mmHg) despite antiglaucoma therapy including timolol twice daily and dorzolamide three times daily in both eyes. Myopia and a history of previous LASIK procedures complicate the diagnosis of glaucoma, including assessment of intraocular pressure, visual field, and optic disc morphology, and also pose challenges in glaucoma therapy. SLT may be an effective treatment option for these patients."

Case report • Clinical • Glaucoma • Ophthalmology

Foreign body removal from the anterior chamber angle after explosive trauma (SOE 2025) - "The intraocular pressure (IOP) OD 26 mm Hg (uses a hypotensive drug (Dorzolamide) twice a day), OS 15 mm Hg... Surgical removal of a metal foreign body from the ACA using a magnetic instrument allows for effective elimination of secondary complications, including ophthalmic hypertension, metallosis with full restoration of visual function. This case emphasizes the importance of timely diagnosis and surgical intervention to preserve vision in patients after explosive trauma."

Ocular Inflammation • Ophthalmology • Uveitis

Thermoresponsive Hydrogels with Tunable Viscoelasticity for Extended Ocular Drug Delivery. (PubMed, Biomacromolecules) - "The release of ophthalmic drugs, brinzolamide, dorzolamide, and dexamethasone, was tuned from 2 weeks to four months by changing drug lipophilicity. The precorneal residence time of glaucoma drug brinzolamide was extended over 48 h after topical administration and over 23 days after subconjunctival injections in rabbits. These findings suggest an approach to improve the viscoelasticity of eye drops and injectables, as well as to prolong drug delivery times via hydrogel systems."

Journal • Glaucoma • Ophthalmology

A case of bilateral stellate nonhereditary idiopathic foveomacular retinoschisis with 14-month follow-up: clinical features, OCT findings and treatment outcome. (PubMed, BMC Ophthalmol) - "Our findings suggest that bilateral SNIFR can occur in non-myopic females, although this patient did not respond to systemic and topical carbonic anhydrase inhibitors."

Journal • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders

Tolerance of Other Carbonic Anhydrase Inhibitors in a Patient With Dorzolamide-Induced Allergic Contact Dermatitis. (PubMed, Contact Dermatitis) - No abstract available

Journal • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents. (PubMed, Mol Divers) - "Main repositioned drugs have included chloroquine, ivermectin, dexamethasone, Baricitinib, tocilizumab, Mab114 (Ebanga™), ZMapp (pharming), Artesunate, imiquimod, saquinavir, capmatinib, naldemedine, Trametinib, statins, celecoxib, naproxen, metformin, ruxolitinib, nitazoxanide, gemcitabine, Dorzolamide, Midodrine, Diltiazem, zinc acetate, suramin, 5-fluorouracil, quinine, minocycline, trifluoperazine, paracetamol, berbamine, Nifedipine, and chlorpromazine. This succinct review will delve into the topic of repositioned drugs that have been utilized to combat emerging and re-emerging viral pathogens."

Journal • Review • Chikungunya • Dengue Fever • Ebola Virus Disease • Hematological Disorders • Hepatology • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Intravitreal Bevacizumab Alone Vs Combined With Topical Timolol-Dorzolamide or Dorzolamide for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. (PubMed, Clin Ophthalmol) - "Randomized controlled trials (RCTs) comparing IVB (1.25 mg, monthly) with topical dorzolamide-timolol (twice daily) or dorzolamide alone (twice daily) were included. Concurrent IVB with topical timolol-dorzolamide or dorzolamide alone demonstrated similar efficacy in improving BCVA and CMT in DME patients. However, the IVB+TD combination resulted in a more significant reduction in IOP compared to IVB alone."

Journal • Retrospective data • Review • Diabetes • Diabetic Macular Edema • Metabolic Disorders • Ophthalmology • Retinal Disorders

Comparison of the Effect of Antiglaucoma Drops with Selective Laser Trabeculoplasty in Patients with Primary Open-angle Glaucoma (ARVO 2025) - "The drug therapy group followed a tiered treatment protocol, starting with Latanoprost and escalating to beta-blockers, followed by Brimonidine and, ultimately, Dorzolamide as necessary to achieve therapeutic targets. Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Glaucoma • Ophthalmology

Melanin Binding Based Design of Carbonic Anhydrase Inhibitors for Prolonged Reduction of Intraocular Pressure (ARVO 2025) - "Three new compounds (low, intermediate, and high melanin binders), and dorzolamide were applied to albino and pigmented rabbits, and IOP was measured with a tonometer...These drug candidates bind to ocular pigment and slowly release the drug in the eye leading to long action of even two weeks. The future pigment-binding glaucoma drug might be instilled at weekly or biweekly intervals in the glaucoma treatment."

Glaucoma • Ophthalmology

Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. (PubMed, J Curr Glaucoma Pract) - "Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. J Curr Glaucoma Pract 2024;18(4):137-141."

Journal • Glaucoma • Ophthalmology

Topical Dorzolamide for Macular Holes: A Randomised, Double-Blind, Placebo-Controlled Trial-Response. (PubMed, Clin Exp Ophthalmol) - No abstract available

Journal • Retinal Disorders

Topical Dorzolamide for Macular Holes: A Randomised, Double-Blind, Placebo-Controlled Trial-Comment. (PubMed, Clin Exp Ophthalmol) - No abstract available

Journal • Retinal Disorders